<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">28420327</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>12</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1471-2377</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>17</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Apr</Month>
              <Day>19</Day>
            </PubDate>
          </JournalIssue>
          <Title>BMC neurology</Title>
          <ISOAbbreviation>BMC Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Clinical predictors for the prognosis of myasthenia gravis.</ArticleTitle>
        <Pagination>
          <StartPage>77</StartPage>
          <MedlinePgn>77</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">77</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12883-017-0857-7</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Clinical predictors for myasthenia gravis relapse and ocular myasthenia gravis secondary generalization during the first two years after disease onset remain incompletely identified. This study attempts to investigate the clinical predictors for the prognosis of Myasthenia Gravis.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Eighty three patients with myasthenia gravis were concluded in this study. Baseline characteristics were analyzed as predictors.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Relapse of myasthenia gravis developed in 26 patients (34%). Generalization developed in 34 ocular myasthenia gravis patients (85%). Other autoimmune diseases were observed more commonly in relapsed myasthenia gravis (P = 0.012). Second generalization group contained more late onset patients (P = 0.021). Ocular myasthenia gravis patients with thymus hyperplasia progressed more rapidly than those with other thymus pathology (P = 0.027). Single onset symptom of ocular myasthenia gravis such as ptosis or diplopia predicted early progression than concurrence of ptosis and diplopia (P = 0.027). Treatment effect including glucocorticoid, pyridostigmine, thymectomy, IVIG, immunosuppressive drugs did not show significant difference between the relapsed and non-relapsed groups. The treatment outcome also showed no difference between the single OMG and second generalized groups.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Occurrence of associated autoimmune disease can serve as a potential predictor for myasthenia gravis relapse. Either ptosis or diplopia, as well as thymic hyperplasia can predict generalization in the first six months.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Lili</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, People's Republic of China. bitljq2012@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yun</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Maolin</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>04</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>BMC Neurol</MedlineTA>
        <NlmUniqueID>100968555</NlmUniqueID>
        <ISSNLinking>1471-2377</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009157" MajorTopicYN="N">Myasthenia Gravis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Myasthenia gravis</Keyword>
        <Keyword MajorTopicYN="N">Ocular</Keyword>
        <Keyword MajorTopicYN="N">Prognosis</Keyword>
        <Keyword MajorTopicYN="N">Relapse</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>1</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>4</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28420327</ArticleId>
        <ArticleId IdType="pmc">PMC5395963</ArticleId>
        <ArticleId IdType="doi">10.1186/s12883-017-0857-7</ArticleId>
        <ArticleId IdType="pii">10.1186/s12883-017-0857-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hong YH, Kwon SB, Kim BJ, Kim BJ, Kim SH, Kim JK, et al.  Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients. J Neurol Sci. 2008;273:10–14. doi: 10.1016/j.jns.2008.05.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2008.05.023</ArticleId>
            <ArticleId IdType="pubmed">18602121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allen JA, Scala S, Jones HR. Ocular myasthenia gravis in senior population: diagnosis, therapy, and prognosis. Muscle Nerve. 2010;41:379–384. doi: 10.1002/mus.21555.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.21555</ArticleId>
            <ArticleId IdType="pubmed">19918767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papapetropoulous TH, Ellul J, Tsibri E. Development of generalized myasthenia gravis in patients with ocular myasthenia. Arch Neurol. 2003;60:1491–1492. doi: 10.1001/archneur.60.10.1491-b.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.60.10.1491-b</ArticleId>
            <ArticleId IdType="pubmed">14568823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mee J, Paine M, Byrne E, King J, Reardon K, O'Day J. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuro opthalmol. 2003;23:251–255. doi: 10.1097/00041327-200312000-00002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00041327-200312000-00002</ArticleId>
            <ArticleId IdType="pubmed">14663303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol. 2003;60:243–248. doi: 10.1001/archneur.60.2.243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.60.2.243</ArticleId>
            <ArticleId IdType="pubmed">12580710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monsul NT, Patwa HS, Knorr AM, Lesser RL, Goldstein JM. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci. 2004;217:131–133. doi: 10.1016/j.jns.2003.08.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2003.08.017</ArticleId>
            <ArticleId IdType="pubmed">14706214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wakata N, Iguchi H, Sugimoto H, Nomoto N, Kurihara T. Relapse of ocular symptoms after remission of myasthenia gravis-a comparison of relapsed and complete remission cases. Clin Neurol Neurosurg. 2003;105:75–77. doi: 10.1016/S0303-8467(02)00104-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0303-8467(02)00104-X</ArticleId>
            <ArticleId IdType="pubmed">12691794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki S, Nishimoto T, Kohno M, Utsugisawa K, Nagane Y, Kuwana M, Suzuki N. Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated myasthenia gravis. J Neuroimmunol. 2013;258:61–66. doi: 10.1016/j.jneuroim.2013.03.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2013.03.001</ArticleId>
            <ArticleId IdType="pubmed">23561592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao ZF, Mo XA, Qin C, Lai YR, Olde Hartman TC. Course and prognosis of myasthenia gravis: a systematic review. Eur J Neurol. 2010;17:913–921. doi: 10.1111/j.1468-1331.2010.03017.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1468-1331.2010.03017.x</ArticleId>
            <ArticleId IdType="pubmed">20402761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sieb JP. Myasthenia gravis. An update for the clinician. Clin Exp Immunol. 2014;175:408–418. doi: 10.1111/cei.12217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cei.12217</ArticleId>
            <ArticleId IdType="pmc">PMC3927901</ArticleId>
            <ArticleId IdType="pubmed">24117026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsu HS, Huang CS, Huang BS, Lee HC, Kao KP, Hsu WH, et al.  Thymoma is associated with relapse of symptoms after transsternal thymectomy for myasthenia gravis. Interact Cardiovasc Thorac Surg. 2006;5:42–46. doi: 10.1510/icvts.2005.116616.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1510/icvts.2005.116616</ArticleId>
            <ArticleId IdType="pubmed">17670509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Men LN, Liu WB, Chen ZG, He XT, Zhang Y, Huang R. Prognostic factors related to recurrence after extended thymectomy in patients with myasthenia gravis. Chin J Neurol. 2008;88:1446–1449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18953847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaretzki A, 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al.  Myasthenia gravis: recommendations for clinical research standards. Task force of the Medical scientific advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55:16–23. doi: 10.1212/WNL.55.1.16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.55.1.16</ArticleId>
            <ArticleId IdType="pubmed">10891897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu HY, Sun ZW, Qin B, Gong T, Zeng XY, Sun YC. Predictors and influencing factors on prognosis of ocular myasthenia gravis. Chin J Neuroimmunol&amp; Neuro. 2010;17:107–109.</Citation>
        </Reference>
        <Reference>
          <Citation>Nakai A, Hayano Y, Furuta F, Noda M, Suzuki K. Control of lymphocyte egress from lymph nodes through β2-adrenergic receptors. J Exp Med. 2014;211:2583–2598. doi: 10.1084/jem.20141132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20141132</ArticleId>
            <ArticleId IdType="pmc">PMC4267238</ArticleId>
            <ArticleId IdType="pubmed">25422496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guereschi MG, Araujo LP, Maricato JT, Takenaka MC, Nascimento VM, Vivanco BC, et al.  Beta2-adrenergic receptor signaling in CD4+ Foxp3+ regulatory T cells enhances their suppressive function in a PKA-dependent manner. Eur J Immunol. 2013;43:1001–1012. doi: 10.1002/eji.201243005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201243005</ArticleId>
            <ArticleId IdType="pubmed">23436577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang LL, Xie YC, Hou SF, Feng K, Yin J, Xu XH. Role of β2-adrenergic receptor polymorphisms in pathogenesis of myasthenia gravis. Chin J Neurol. 2009;42:828–832.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang LL, Zhang Y, He ML. Role of β2-adrenergic receptor polymorphisms in prognosis of myasthenia gravis with other autoimmune diseases. Chin J Neurol. 2015; 48:390–4.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang LL, Zhang Y, He ML. Clinical characteristics of patients with myasthenia gravis associated with other autoimmune diseases. Chin J Contemp Neurol Neurosurg. 2014;14:873–877.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang LL, Zhang Y, He ML. Study of the association of β2-adrenergic receptor gene polymorphism with myasthenia gravis associated with thymus abnormality. Natl Med J China 2015; 95:1518–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26178506</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
